Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin
Article first published online: 26 NOV 2008
© 1994 British Journal of Urology
British Journal of Urology
Volume 74, Issue 2, pages 195–199, August 1994
How to Cite
POPERT, R. J. M., GOODALL, J., COPTCOAT, M. J., THOMPSON, P. M., PARMAR, M. K. B. and MASTERS, J. R. W. (1994), Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. British Journal of Urology, 74: 195–199. doi: 10.1111/j.1464-410X.1994.tb16585.x
- Issue published online: 26 NOV 2008
- Article first published online: 26 NOV 2008
- Accepted for publicatin 26 November 1993
- superficial bladder cancer;
Objective To determine the response of a marker tumour to a single instillation of intravesical epirubicin.
Patients and methods Eighty-one patients (54 men, 27 women) with a mean age of 69.3 years (range 36–92) with superficial bladder cancer were randomized to receive a single instillation of intravesical epirubicin. At the initial cystoscopy all but one papillary marker tumour was resected. Subsequently the patients were a randomized to receive either intravesical epirubicin at a concentration of 1 mg/ml (n=40) or 2 mg/ml (n=41) in 50 ml of saline for 1h. THe response of the marker tumour was determined at 3 months (first check cystoscopy). The toxicity associated with both treatments was also recorded.
Results A complete response (no visible or microscopic bladder carcinoma) was observed in 46% (95% confidence interval (CI) 35–57%) of a patients. No patient experienced systemic side-effects. Chemical cystitis and bladder irritability were the most frequent local sideeffects, occurring in 15% (95% CI 8 - 24%) of the patients.
Conclusions A single instillation of intravesical epirubicin has a demonstrable effect in superficial bladder cancer. The results compare farvourably with more onerous regimes. Side-effects were minimal at 1 mg/ml and acceptable at 2 mg/ml.